Actively Recruiting
Reduced MBF Regimen for Patients >=55 Years With Myeloid Malignancies
Led by Shanghai Jiao Tong University School of Medicine · Updated on 2026-03-17
61
Participants Needed
2
Research Sites
265 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
In this multiple-center phase II study, the aim is to evaluate the clinical outcome of reduced intensity conditioning regimen with fludarabine (150mg/m2), busulfan (6.4mg/kg) and melphalan (100mg/m2) in patients with myeloid malignancies including AML, MDS and CMML \>=55 years.
CONDITIONS
Official Title
Reduced MBF Regimen for Patients >=55 Years With Myeloid Malignancies
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 55-65
- Patients with HLA-matched sibling donors, 9-10/10 matched unrelated donors, or haplo-identical donors
- Patients with AML in remission, or MDS in any stage, or CMML in any stage
- Informed consent provided
You will not qualify if you...
- Patients with abnormal liver function greater than 3 times normal
- Patients with renal function greater than 1.5 times normal
- Patients with abnormal cardiac function
- Patients with active infection
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 2 locations
1
Blood & Marrow Transplantation Center, RuiJin Hospital
Shanghai, Shanghai Municipality, China, 200025
Actively Recruiting
2
Shanghai No 6 Hospital
Shanghai, China
Actively Recruiting
Research Team
J
Jieling Jiang
CONTACT
J
jiong HU
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here